Covid-19
WHO: Vaccine inequity undermining global economic recovery.
23 Jul, 2021 | 10:53h | UTCNews release: Vaccine inequity undermining global economic recovery – World Health Organization
Dashboard: Global Dashboard for Vaccine Equity
Commentaries: Urgent need for COVID-19 vaccine equity – University of Oxford AND COVID-19 Vaccine Inequity Undermines Global Economic Recovery – Health Policy Watch
Commentary on Twitter (thread – click for more)
COVID-19 vaccine inequity is undermining 🌍 economic recovery. 🆕WHO, @UNDP and @BlavatnikSchool Dashboard on #VaccinEquity finds that low-income countries would add $38B to their GDP forecast if they had the same vaccination rate as high-income countrieshttps://t.co/BsYF2eYL1G
— World Health Organization (WHO) (@WHO) July 22, 2021
Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.
23 Jul, 2021 | 10:51h | UTCTocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet
Related: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. AND M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. AND RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes AND Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. AND M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.
Perspective | SARS-CoV-2 human challenge studies — establishing the model during an evolving pandemic.
23 Jul, 2021 | 10:49h | UTCRelated: World’s first coronavirus “Human Challenge” study receives ethics approval in the UK (several texts on the subject) AND Are SARS-CoV-2 Human Challenge Trials Ethical? – “A clinical trial is underway in the UK in which young, healthy participants are exposed deliberately to SARS-CoV-2 to assess the viral inoculum needed to produce an infection and to test vaccine efficacy”.
Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients.
23 Jul, 2021 | 10:47h | UTC
How the Delta variant achieves its ultrafast spread – “Viral load is roughly 1,000 times higher in people infected with the Delta variant than those infected with the original coronavirus strain, according to a study in China”.
23 Jul, 2021 | 10:46h | UTCHow the Delta variant achieves its ultrafast spread – Nature
What are the Delta, Gamma, Beta and Alpha Covid variants?
23 Jul, 2021 | 10:45h | UTCWhat are the Delta, Gamma, Beta and Alpha Covid variants? – BBC
Related: Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”. AND WHO renames COVID-19 variants with the Greek alphabet (i.e., Alpha, Beta, Gamma, etc), making them simple, easy to say and remember. The naming system aims to prevent calling COVID-19 variants by the places where they are detected, which is stigmatizing & discriminatory.
The Lambda variant: is it more infectious, and can it escape vaccines? A virologist explains.
23 Jul, 2021 | 10:43h | UTCRelated: Lambda, the Newest WHO Variant of Interest, is Now in 29 Countries – Health Policy Watch
Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.
22 Jul, 2021 | 11:16h | UTCCommentaries: Study Finds Pfizer And AstraZeneca Vaccines Effective Against The Delta Variant — As Long As You Get Both Doses – Forbes AND Pfizer’s COVID-19 vaccine works very well against the Delta variant — but only after 2 doses – Insider
Related: [Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant. AND Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. AND Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.
Commentary on Twitter
Public Health England's test-negative case-control study for Delta variant now in NEJM: over 14,000 people with Alpha, over 4,000 with Delta https://t.co/3l1QhKeXBT
Vax effectiveness against testing positive for Delta after 2 doses:
– BNT-Pfizer 88.0% (85-90)
– AZ 67.0% (61-72) pic.twitter.com/9UFy6CLSWw— Hilda Bastian, PhD (@hildabast) July 21, 2021
COVID-19 antibodies persist at least nine months after infection – “98.8 percent of people infected in February/March showed detectable levels of antibodies in November”.
22 Jul, 2021 | 11:14h | UTCNews release: COVID-19 antibodies persist at least nine months after infection – Imperial College London
Original study: SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’ – Nature Communications
RCT: Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 – safe, but no statistically significant risk reduction in organ dysfunction or death.
22 Jul, 2021 | 11:08h | UTCCommentary: Dapagliflozin in patients with COVID-19: truth or dare – The Lancet Diabetes & Endocrinology
Should children get COVID vaccines? What the science says.
22 Jul, 2021 | 11:06h | UTCShould children get COVID vaccines? What the science says – Nature
Analysis finds benefits of COVID-19 vaccination outweigh risks of rare cases of myocarditis.
22 Jul, 2021 | 11:05h | UTCNews release: Study finds benefits of COVID-19 vaccination outweigh risks of rare cases of myocarditis – American Heart Association
Original study: Myocarditis with COVID-19 mRNA Vaccines – Circulation
Commentary: Myocarditis and COVID-19 Vaccines: New Review Tackles Knowns, Unknowns – TCTMD
Commentary on Twitter
Just published ahead of print- Myocarditis with Covid mRNA Vaccines https://t.co/mc2yrr5pDV Mechanisms, benefit of COVID-19 mRNA vaccination over low risk, management strategies – review of all myocarditis cases published to date, CDC&other reports @PeterHotez @ishannovation
— BiykemBozkurt (@BiykemB) July 20, 2021
Opinion | The benefits of a COVID vaccine far outweigh the small risk of treatable heart inflammation.
22 Jul, 2021 | 10:57h | UTC
Opinion | Kids aren’t just littler adults – here’s why they need their own clinical trials for a COVID-19 vaccine.
22 Jul, 2021 | 10:55h | UTC
More than 1.5 million children lost a primary or secondary caregiver due to the COVID-19 pandemic.
21 Jul, 2021 | 10:52h | UTCNews release: More than 1.5 million children lost a primary or secondary caregiver due to the COVID-19 pandemic – NIH News Releases
Original study: Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study – The Lancet
Invited commentary: Answering the call to support youth orphaned by COVID-19 – The Lancet
Related: Covid-19 Has Created Thousands Of Newly Single Parents And Orphans
Commentary on Twitter (thread – click for more)
NEW—Over 1.5 million children lost a parent, custodial grandparent, or other relative who cared for them during the first 14 months of the #COVID19 #pandemic, first global study estimates.
🔗 Read https://t.co/Ug2ADTvO8G (1/2)
— The Lancet (@TheLancet) July 20, 2021
Exploring the gap between excess mortality and COVID-19 deaths in 67 countries.
21 Jul, 2021 | 10:51h | UTCExploring the Gap Between Excess Mortality and COVID-19 Deaths in 67 Countries – JAMA Network Open
Report: Three new estimates of India’s all-cause excess mortality during the COVID-19 Pandemic – pandemic death toll estimated to be between 3.4 million and 4.9 million excess deaths.
21 Jul, 2021 | 10:49h | UTCCommentaries: India’s pandemic death toll could be in the millions – Associated Press AND Covid-19: India excess deaths cross four million, says study – BBC AND India’s true pandemic death toll is likely to be well over 3 million, a new study finds. – The New York Times AND India’s excess deaths during Covid ‘could be 10 times official toll’ – The Guardian
Commentary on Twitter
India's official COVID death toll is 400,000.
But new research shows the death toll could be much higher, up to 4 million.
↘️ @abhishekecon @JustinSandefur & @arvindsubraman breakdown the numbers from three data estimates: https://t.co/rdOcZvHZQU.
— Center for Global Development (@CGDev) July 20, 2021
Perspective | Potential COVID-19 endgame scenarios: eradication, elimination, cohabitation, or conflagration?
21 Jul, 2021 | 10:48h | UTC
Is the cure really worse than the disease? The health impacts of lockdowns during COVID-19 – “While there are certainly costs to be expected from intervening against COVID-19—every decision has a cost, after all—the counterfactual of an unmitigated epidemic makes these restrictions far less damaging than some have suggested”.
21 Jul, 2021 | 10:46h | UTCCommentaries: Expert reaction to a narrative review looking at the health impacts of lockdowns – Science Media Centre AND Lockdowns do not harm health more than Covid, say researchers – The Guardian
Commentary on Twitter (thread – click for more)
The smiley faces, cherry blossoms, Great Barrington Declaration fans, "natural herd immunity" enthusiasts & anti-maskers do not approve of our new @GlobalHealthBMJ analysis on lockdowns 😉
So, here's a long-ish thread on what we did & did not find 1/nhttps://t.co/CFtT9j44vo
— Prof. Gavin Yamey MD MPH (@GYamey) July 20, 2021
Cohort study: Sickle cell disorders and severe COVID-19 outcomes – “Our analysis estimated a 4-fold increased risk for COVID-19–related hospitalization and a 2.6-fold increased risk for COVID-19–related death for sickle cell disease”.
21 Jul, 2021 | 10:44h | UTCSickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study – Annals of Internal Medicine
WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19).
20 Jul, 2021 | 10:29h | UTCRelated Guidance: AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.” AND ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia
WHO and UNICEF warn of a decline in vaccinations during COVID-19.
20 Jul, 2021 | 10:27h | UTCWHO and UNICEF warn of a decline in vaccinations during COVID-19 – World Health Organization
Related: Millions of children worldwide missed routine vaccinations during the pandemic, study suggests.
WHO warns that HIV infection increases risk of severe and critical COVID-19.
20 Jul, 2021 | 10:24h | UTCNews release: WHO warns that HIV infection increases risk of severe and critical COVID-19 – World Health Organization
Commentary on Twitter (thread – click for more)
🆕 report confirms that #HIV infection is a significant independent risk factor for both severe/critical #COVID19 presentation at hospital admission & in-hospital mortality. 23.1% of all people living with HIV who were hospitalized with COVID-19, died.
👉 https://t.co/UBd0OyFKnd pic.twitter.com/UHLo9RPa1g
— World Health Organization (WHO) (@WHO) July 16, 2021
International Registry: Ischemic and hemorrhagic stroke among critically ill patients with Covid-19.
20 Jul, 2021 | 10:21h | UTCRelated: SARS-CoV-2 and Stroke Characteristics – higher rate of large vessel occlusions and stroke in young patients AND Case series of 18 male adults aged 50 years or younger with acute ischemic stroke during the convalescent phase of asymptomatic Covid-19 AND Case-control study: COVID-19-associated stroke is associated with worse outcomes and increased mortality AND Pictorial essay: Neurological emergencies associated with COVID-19: stroke and beyond AND Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke AND Risk of Ischemic Stroke in Patients with COVID-19 vs. Patients with Influenza
Editorial: Defining covid-19 elimination.
20 Jul, 2021 | 10:20h | UTCDefining covid-19 elimination – The BMJ